About us
Strategic intelligence for the radiation healthcare
Bringing value to businesses and investors!
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiopharmaceutical, cyclotron, proton therapy and brachytherapy.
We offer the most comprehensive set of reports and directories, with over 4,900 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.
We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts.
We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeated satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. The team brings together more than 50 years of expertise in the field of radiation healthcare.
In 2024, MEDraysintell was integrated into NucAdvisor which is a nuclear consulting company, subsidiary of Soletanche Freyssinet (VINCI Group) established in France by a group of senior executives from across the nuclear research and industry. Visit NucAdvisor’s website to learn more about this company www.nucadvisor.com
The Team
The team brings together years of expertise in the field of radiation healthcare.
Dr. Vincent Brechin is a global medical scientist and industry expert, holding a PhD in Medical Sciences from the University of Tokyo, along with advanced research credentials from the Mount Sinai School of Medicine in New York City and the University of Lyon.
In 2024, Dr. Brechin joined NucAdvisor-MEDraysintell as a Senior Consultant, where he delivers strategic consulting, comprehensive audits, technological surveillance, and in-depth market analysis. His work extends to advanced database management, offering data-driven insights that support business decisions and market positioning.
With over a decade of leadership in laboratory research, management, and technology-driven innovation, Dr. Brechin has built a strong specialization in oncology, RNA therapeutics, and the science of aging. His deep expertise in cutting-edge medical research directly informs his contributions to the NucAdvisor-MEDraysintell report, where he provides critical analysis on emerging medical technologies and market trends, helping clients navigate complex scientific landscapes and capitalize on growth opportunities.
Paul-Emmanuel Goethals founded CSIntell in 2012 followed by MEDraysintell in 2013. He has 35 years of experience in consulting, business development-intelligence and investor relations with a unique understanding of the medical and healthcare markets, especially in Radiotherapy, Radiopharmacy. Throughout these years he made numerous reports on complex markets as well as outstanding company profiles at the full satisfaction of his successive clients.
Paul-Emmanuel holds an MBA from the University of Dallas and is a member of SCIP (Strategic and Competitive Intelligence Professionals, Texas, USA).
Prior founding MEDraysintell and CSIntell, Paul-Emmanuel was Vice President Business Development & Capital Markets and Special Counsel to the CEO at Eckert & Ziegler Group; Director Corporate Business Development & Investor Relations at IBA; Project Manager at Strategic Analysis Inc.; Finance Director & Board member at Evening Group SA, and Marketing Specialist & Product Management at Chemviron Carbon.
Nicolas Mario is an experienced nuclear engineer specialised in nuclear medicine. He joined the MEDraysintell team following its integration into NucAdvisor in 2024. He has 13 years of experience in the radionuclide manufacturing industry, acquired through involvement in new build manufacturing projects worldwide (in Jordan, the Netherlands, South Africa, Bolivia, etc.) and consulting projects for public and private stakeholders, including industrial players across the entire supply chains, such as Curium, Urenco, Blue Earth Therapeutics.
Since 2017, Nicolas Mario has been a key contributor to the SAMIRA initiative. His support to the European Commission culminated in the SAMIRA action plan and the European Radioisotope Valley Initiative (ERVI).
As a senior consultant, Nicolas Mario is a trusted advisor who conducts a range of studies for public and private stakeholders. His expertise in feasibility studies, optioneering studies, technology assessments, and market research is highly regarded. Since fall 2024, Nicolas is following an executive MBA program with a specialisation in Healthcare Innovation & Technology at EDHEC Business School in Paris.
Dr. Richard ZIMMERMANN
Dr. Richard Zimmermann founded Chrysalium Consulting in 2012 and MEDraysintell in 2013. He is a chemistry engineer, with a PhD degree in organic chemistry obtained in 1984 from the University of Strasbourg, France followed by a post-doctoral at Georgetown University, Washington, DC.
He has 15 years of experience in research laboratories of conventional pharmaceutical companies (Beecham, Solvay Pharmaceuticals) in France, Germany and the Netherlands. And over 25 years’ experience in the radiopharmaceutical industry as head of Research & Development and business development (CIS bio, Schering Pharma, IBA Molecular).
He is the owner of Chrysalium Consulting, Co-founder of Global Morpho Pharma, Founder and President of the Oncidium Foundation, Co-founder of rad4med.be and Telix Pharmaceuticals Ltd., and former President of Medisystem and ANMI.
Member of 6 Scientific Advisory Boards.
OUR Office
Nicolas Mario
Courbevoie, France
Phone: +33 (0)1 40 88 41 40
nicolas.mario@nucadvisor.com
Vincent Bréchin
Courbevoie, France
Phone: +33 (0)1 40 88 41 40
vincent.brechin@nucadvisor.com
